As many studies demonstrated that over activated PI3K/AKT pathway activity may lead to DDP resistance in malignant cells [29,30], inhibition of this signaling pathway increased the sensitivity of cancer cells to DDP treatment [29-33], and combined treatment of PI3K inhibitors with DDP also got promising results [34]. This evidence concerns the gene AKT1 and cancer.